Specific molecular recognition by proteins is the basis of their roles in biocatalysis, signal transduction, metabolism and pathogenesis 1 . Almost all drugs essentially act by interaction with proteins by modulating their activities. Till recently, it was believed that this specificity was critical for all the biological processes and rested on the integrity of the structure of proteins. Lately, both of these premises have been challenged. Protein disorder has been found to be as important as ordered structure [1] [2] [3] . The catalytic promiscuity and moonlighting shown by a large number of proteins indicate that not only protein specificity has been overrated but also the non-specificity manifested in these two phenomena is biologically relevant [4] [5] [6] [7] . Here we provide an update on the roles of protein moonlighting that are relevant to medical sciences.
What is protein moonlighting?
In the beginning, as living organisms shifted from the RNA world to the DNA world (and central dogma started dictating protein synthesis), the number of enzymes actually was not large and enzymes had broad specificity (also referred to in the literature as substrate promiscuity) 8 . Evolution created more complex organisms, creating needs for a large number of enzymes/proteins and regulation of their biological activities. This led to more efficient and specific enzymes. In fact, the two traits at the molecular design level are not unrelated. Enzyme specificity is quantified by k cat /K m and thus involves the catalytic rates 9 . Hence, while our appreciation of the importance of protein non-specificity may be rather recent, these molecules inherently were designed to be non-specific; it was the evolutionary need which led to some becoming highly specific.
The protein diversification involves multiple mechanisms: mutation, gene duplication and horizontal gene transfer. In 1989, Piatigorsky and [10] [11] [12] . The same has been shown as determinant for treatment endpoint for the pulmonary tuberculosis 13 . Moonlighting, in majority of cases, involves different binding sites on a protein. The glycolytic enzyme glucoisomerase is known to act as a cytokine, nerve growth factor and promoter of cell differentiation factor 6, 7 . Some other examples of moonlighting proteins are crystallins, lactate dehydrogenase, enolase and quinine oxidoreductase.
Disordered proteins are induced to acquire the desired conformation; so, while preformed binding site is not always required, a macromolecular nature may facilitate the formation of inducible binding site [3] [4] [5] [6] [7] [8] . Both catalytic promiscuity and moonlighting reflect that biological specificity is not an essential virtue of proteins/enzymes. The level of protein 
Medical implications of protein moonlighting
Viewpoint expression and metabolic flux (of substrates and ligands) are more important than believed so far. In the former case, the focus has been on the formation of inclusion bodies. For latter, importance seems to go beyond regulation through feedback inhibition/ allosteric interactions. The shift in our view of proteins from a static to inducible conformation (more flexible) happened long ago. The current view of many similar conformations in equilibria seems to be in line with the roles of substrates/ligands as the latter will shift these equilibria. Furthermore, the sanctity of active site turns out to be an invalid concept -it is the combinations of weak interactions which initiate the binding and chemistry of the local amino acid residues which define/dictate the biological activity. The moonlighting requires proteins/enzymes to be macromolecular.
Promiscuity, moonlighting and disorder
The above three terms refer to the emerging paradigm shifts in our understanding of the protein structure and function. It is necessary to clarify how promiscuity and moonlighting differ and how these are related to disorder, at least in some cases. 14 . The list also includes post-translational modifications and proteins which catalyze multisteps in a metabolic pathway 15 . One key difference between promiscuity and moonlighting is that the former involves same active site/region (as for the main activity) whereas moonlighting activities reside at different sites on the protein. It was because these activities were originally coded by different genes which fused into a single one during evolution. The evolution of these two different kinds of multifunctional proteins in archaea has been reviewed by Jia et al 15 . The promiscuity in both Embden-Meyerhof-Parnas (EMP) and Entner-Doudoroff pathway found in archaea indicated that these organisms used promiscuity to utilize available nutrients with limited set of enzymes. The above review also points out that the proteins of archaea are rich in disorder 15 . It seems likely that disorder plays a more important role in promiscuity as it requires same binding site accommodating very different kinds of substrates. The disorder also plays an important role in moonlighting as well 16 .
How moonlighting impacts medical sciences?
Sriram et al 17 have pointed out the various factors which can complicate prediction of phenotype from genotype in cases of single gene disorders. If the metabolic enzyme responsible for the disorder has (unknown) moonlighting activities, these complicate the clinical phenotype picture. Phosphoglucoisomerase deficiency is responsible for haemolytic anaemia, but its neuroleukin activity may lead to neurological defects as well. Glycerol kinase has many moonlighting activities. The mutation(s) in its gene can result in a variety of phenotypes which have been difficult to predict 17 . There is enough evidence that moonlighting activities of glyceraldehydes-3-phosphate dehydrogenase play a role in many neurodegenerative diseases including Huntington, Alzheimer's and Parkinson's diseases. A clear indication is that several promising drugs for Alzheimer's disease decrease the expression of these enzymes. Further, ceruloplasmin has been extensively studied as a protein with several intriguing moonlighting activities 18 . Aceruloplasminaemia and haemochromatosis lead to systemic haemosiderosis and diabetes while the former alone results in neural and retinal degeneration 18 . Elevated levels of this protein are associated with several inflammatory processes and metastatic cancers. While it acts as a protection against oxygen reactivity, when localized in the vessel walls, the available copper ions switch its activity to cause oxidative damage to the invading pathogen 18 .
Moonlighting proteins as virulence factors
While it has been suggested that many glycolytic enzymes are found on the cell surface of Gram-positive organisms, the work from Götz's laboratory 19 shows that in methicillin-resistant Staphylococcus aureus, two cytoplasmic enzymes of EMP, fructose-1,6-bisphosphate aldolase and glyceraldehyde phosphate dehydrogenase moonlight in their secretory forms. These enzymes were shown not only to enhance the binding of the bacterium to host cells but also binding to some host matrix proteins. In fact, moonlighting activity has emerged as a mechanism of virulence in several cases 20 . Furthermore, during evolutionary phase, Mycobacterium tuberculosis assigned newer roles to proteins, many of these have virulence attributes 21 . Isocitrate dehydrogenase and aconitase of M. tuberculosis are examples of moonlighting proteins 22, 23 . the bacterium in the macrophages 24 . M. tuberculosis peptidyl-prolyl isomerases (PPIases) show immunological and chaperone-like activity though these do not carry the crystallin motif 25, 26 . There is another interesting aspect of moonlighting activity in the case of M. tuberculosis with respect to its developing antibiotic resistance towards ciprofloxacin 27 . Glutamate racemase is an enzyme important for the cell wall synthesis by producing D-glutamate. The enzyme also showed DNA gyrase inhibition activity thereby creating resistance towards the antibiotic. It is likely that this may turn out to be a more general phenomenon. There are many more examples of moonlighting where a protein displays many other functions [28] [29] [30] [31] . Moonlighting also complicates the drug discovery approaches. A drug is a targeted molecule designed to inhibit a particular protein function. It is often difficult to predict how it will impact the moonlighting activities. It is likely that in several cases, the side effects of a drug may originate in the affected moonlighting activities. The current methods (gene knockouts, antisense RNA or RNA interference) which have proved invaluable in establishing the genotype-phenotype correlations now need to be relooked in light of moonlighting activities.
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Concluding remarks
The overview by James and Tawfik 32 provides a broader perspective on the functional diversity which originates from the protein flexibility; the most extreme case of that being proteins with varying extent of disorder. Not only that facilitates catalysis and signal transduction (especially through post-translational modifications) but also seems to be a prerequisite for the evolution of new and diverse kinds of proteins. Thus, moonlighting is a part of the overall evolutionary design 33 . Just as understanding the phenomenon of isoenzymes paved the way for valuable diagnostic applications several decades ago, appreciation of these 'new views' about protein structure-function correlation will be useful for developing future contours of the practice of medicine. 
